85 related articles for article (PubMed ID: 20697266)
1. Characterization of a new monoclonal antibody against PAX5/BASP in 1525 paraffin-embedded human and animal tissue samples.
Agostinelli C; Sabattini E; Gjørret JO; Righi S; Rossi M; Mancini M; Piccaluga PP; Bacci F; Marafioti T; Bettini G; Falini B; Pileri SA
Appl Immunohistochem Mol Morphol; 2010 Dec; 18(6):561-72. PubMed ID: 20697266
[TBL] [Abstract][Full Text] [Related]
2. Pax5 immunostaining in paraffin-embedded sections of canine non-Hodgkin lymphoma: a novel canine pan pre-B- and B-cell marker.
Willmann M; Müllauer L; Guija de Arespacochaga A; Reifinger M; Mosberger I; Thalhammer JG
Vet Immunol Immunopathol; 2009 Apr; 128(4):359-65. PubMed ID: 19100628
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic uses of Pax5 immunohistochemistry.
Feldman AL; Dogan A
Adv Anat Pathol; 2007 Sep; 14(5):323-34. PubMed ID: 17717432
[TBL] [Abstract][Full Text] [Related]
4. Pax5 expression in non-Hodgkin's lymphomas and acute leukemias.
Zhang X; Lin Z; Kim I
J Korean Med Sci; 2003 Dec; 18(6):804-8. PubMed ID: 14676435
[TBL] [Abstract][Full Text] [Related]
5. PAX8 and PAX5 are differentially expressed in B-cell and T-cell lymphomas.
Morgan EA; Pozdnyakova O; Nascimento AF; Hirsch MS
Histopathology; 2013 Feb; 62(3):406-13. PubMed ID: 23163626
[TBL] [Abstract][Full Text] [Related]
6. The utility of PAX5 immunohistochemistry in the diagnosis of undifferentiated malignant neoplasms.
Jensen KC; Higgins JP; Montgomery K; Kaygusuz G; van de Rijn M; Natkunam Y
Mod Pathol; 2007 Aug; 20(8):871-7. PubMed ID: 17529924
[TBL] [Abstract][Full Text] [Related]
7. Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody.
Agostinelli C; Paterson JC; Gupta R; Righi S; Sandri F; Piccaluga PP; Bacci F; Sabattini E; Pileri SA; Marafioti T
Histopathology; 2012 Jul; 61(1):33-46. PubMed ID: 22394247
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Pax5 expression and comparison with BLA.36 and CD79αcy in feline non-Hodgkin lymphoma.
Felisberto R; Matos J; Alves M; Cabeçadas J; Henriques J
Vet Comp Oncol; 2017 Dec; 15(4):1257-1268. PubMed ID: 27549353
[TBL] [Abstract][Full Text] [Related]
9. PAX5 expression in nonhematopoietic tissues. Reappraisal of previous studies.
Morgenstern DA; Hasan F; Gibson S; Winyard P; Sebire NJ; Anderson J
Am J Clin Pathol; 2010 Mar; 133(3):407-15. PubMed ID: 20154279
[TBL] [Abstract][Full Text] [Related]
10. Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis.
Mhawech-Fauceglia P; Saxena R; Zhang S; Terracciano L; Sauter G; Chadhuri A; Herrmann FR; Penetrante R
J Clin Pathol; 2007 Jun; 60(6):709-14. PubMed ID: 16837628
[TBL] [Abstract][Full Text] [Related]
11. PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia.
Tiacci E; Pileri S; Orleth A; Pacini R; Tabarrini A; Frenguelli F; Liso A; Diverio D; Lo-Coco F; Falini B
Cancer Res; 2004 Oct; 64(20):7399-404. PubMed ID: 15492262
[TBL] [Abstract][Full Text] [Related]
12. PAX immunoreactivity identifies alveolar rhabdomyosarcoma.
Sullivan LM; Atkins KA; LeGallo RD
Am J Surg Pathol; 2009 May; 33(5):775-80. PubMed ID: 19145202
[TBL] [Abstract][Full Text] [Related]
13. The utility of PAX8 in comparison with PAX5 immunohistochemical staining in the diagnosis of Hodgkin lymphoma.
Ameli F; Zahavi Z; Kosari F; Soleimani V
Ann Diagn Pathol; 2022 Oct; 60():151974. PubMed ID: 35926290
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical profiles of 30 monoclonal antibodies against cytokeratins 8, 18 and 19. Second report of the TD5 workshop.
Nap M; van Wel T; Andrés C; Bellanger L; Bodenmüller H; Bonfrer H; Brundell J; Einarsson R; Erlandsson A; Johansson A; Leca JF; Meier T; Seguin P; Sjödin A; Stigbrand T; Sundström BE; van Dalen A; Wiebelhaus E; Wiklund B; Hilgers J
Tumour Biol; 2001; 22(1):4-10. PubMed ID: 11054021
[TBL] [Abstract][Full Text] [Related]
15. Utilization of monoclonal antibody L26 in the identification and confirmation of B-cell lymphomas. A sensitive and specific marker applicable to formalin-and B5-fixed, paraffin-embedded tissues.
Cartun RW; Coles FB; Pastuszak WT
Am J Pathol; 1987 Dec; 129(3):415-21. PubMed ID: 3322020
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic utility of the B-cell lineage markers CD20, CD79a, PAX5, and CD19 in paraffin-embedded tissues from lymphoid neoplasms.
Adams H; Liebisch P; Schmid P; Dirnhofer S; Tzankov A
Appl Immunohistochem Mol Morphol; 2009 Mar; 17(2):96-101. PubMed ID: 18838917
[TBL] [Abstract][Full Text] [Related]
17. A new monoclonal anti-CD3epsilon antibody reactive on paraffin sections.
Alibaud L; Llobera R; Al Saati T; March M; Delsol G; Rubin B
J Histochem Cytochem; 2000 Dec; 48(12):1609-16. PubMed ID: 11101629
[TBL] [Abstract][Full Text] [Related]
18. N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas.
Moretti L; Medeiros LJ; Kunkalla K; Williams MD; Singh RR; Vega F
Mod Pathol; 2012 Feb; 25(2):231-6. PubMed ID: 22037256
[TBL] [Abstract][Full Text] [Related]
19. Utility of PAX8 mouse monoclonal antibody in the diagnosis of thyroid, thymic, pleural and lung tumours: a comparison with polyclonal PAX8 antibody.
Toriyama A; Mori T; Sekine S; Yoshida A; Hino O; Tsuta K
Histopathology; 2014 Oct; 65(4):465-72. PubMed ID: 24592933
[TBL] [Abstract][Full Text] [Related]
20. Immunophenotyping of hematologic neoplasms in paraffin-embedded tissue sections.
Davey FR; Elghetany MT; Kurec AS
Am J Clin Pathol; 1990 Apr; 93(4 Suppl 1):S17-26. PubMed ID: 2180277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
